SANDOSTATIN LAR

LOE Approaching

octreotide acetate

NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17

Mechanism of Action

hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin,…

Indications (1)

Clinical Trials (5)

NCT01744249Phase 2/3Unknown

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Started Nov 2011
255 enrolled
Neuroendocrine TumorsAdvanced Cancer
NCT01424241Phase 4Completed

Effects of Sandostatin LAR® in Acromegaly

Started Oct 2006
21 enrolled
Acromegaly
NCT01278342Phase 4Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Started Sep 2006
70 enrolled
Acromegaly
NCT00376064Phase 4Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Started Mar 2006
20 enrolled
Acromegaly
NCT00372697Phase 3Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Started Dec 2005
28 enrolled
Acromegaly